Zogenix

Zogenix

Developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases
San Diego United States (HQ)
Deals in the last 12 months undisclosed

Zogenix Company information

Edit
Launch date
Employees
182 people
Ownership
Market cap
$1.0b
Net debt
$271m
Firm valuation
€673m (Public information from 2020)
USD20162017201820192020E2021E2022E
Revenues-9m-3m12m92m227m
% growth----300 %667 %147 %
EBITDA-(93m)(142m)(429m)1.0b1.1b-
% EBITDA margin-(1033 %)-(14300 %)8625 %1221 %-
Profit-(127m)(124m)(420m)(190m)(147m)(30m)
% profit margin-(1411 %)-(14000 %)(1583 %)(160 %)(13 %)
EV / Revenue-110.0x-564.0x58.6x8.8x4.5x
EV / EBITDA--11.5x-7.1x-4.8x0.7x0.7x-
  • Edit
DateInvestorsAmountRound
-N/A
N/A$3.1mDEBT
N/A$36mSERIES B
N/A$35mSERIES B
$15mLATE VC
N/AN/AIPO
Total Funding€149m

Recent News about Zogenix

Edit
LocationEdit
United States, San Diego

Investments by Zogenix

Edit
Are you an employee or an investor of this company?
Add your profile